|
FY2013
12 months to Dec 31, 2013
|
FY2012
12 months to Dec 31, 2012
|
FY2011
12 months to Dec 31, 2011
|
FY2010
12 months to Dec 31, 2010
|
|
|---|---|---|---|---|
| OPERATING ACTIVITIES: | ||||
| Consolidated net (loss) income | ||||
| Adjustments to reconcile consolidated net (loss) income to Net cash provided by operating activities: | ||||
| Depreciation and amortization | ||||
| Stock-based compensation | ||||
| Amortization of debt issuance costs and premium / discount | ||||
| Provision for bad debts | ||||
| Selling, general and administrative expenses paid in shares of common stock | ||||
| Deferred income taxes | ||||
| Net loss on disposal of property, plant and equipment | ||||
| Loss on auction-rate securities rights | ||||
| Impairment of long-lived assets | ||||
| Gain on trading securities | ||||
| Change in fair value of acquisition-related contingent consideration | ||||
| Loss on extinguishment of debt | ||||
| Asset impairment charges | ||||
| Gain on sale of business | ||||
| Changes in assets and liabilities which (used) provided cash: | ||||
| Accounts receivable | ||||
| Inventories | ||||
| Prepaid and other assets | ||||
| Accounts payable | ||||
| Accrued expenses | ||||
| Other liabilities | ||||
| Income taxes payable/receivable | ||||
| Net cash provided by operating activities | ||||
| INVESTING ACTIVITIES: | ||||
| Purchases of property, plant and equipment | ||||
| Proceeds from sale of property, plant and equipment | ||||
| Proceeds from investments | ||||
| Acquisitions, net of cash acquired | ||||
| Proceeds from sale of investments | ||||
| Proceeds from sales of trading securities | ||||
| Purchases of investments | ||||
| Other investments | ||||
| Patent acquisition costs and license fees | ||||
| Proceeds from sale of business, net | ||||
| Settlement escrow | ||||
| Increase in restricted cash and cash equivalents | ||||
| Net cash used in investing activities | ||||
| FINANCING ACTIVITIES: | ||||
| Capital lease obligations repayments | ||||
| Direct financing arrangement repayments | ||||
| Proceeds from issuance of notes | ||||
| 5.75% Senior Notes Due 2022 | ||||
| 7.00% Senior Notes Due 2019 and 7.25% Senior Notes due 2022 | ||||
| Total proceeds from issuance of notes | ||||
| Proceeds from issuance of 2020 Notes | ||||
| Proceeds from issuance of Term Loans | ||||
| Proceeds from other indebtedness | ||||
| Principal payments on Term Loans | ||||
| Payment on AMS Convertible Notes | ||||
| Principal payments on HealthTronics, Inc. senior credit facility | ||||
| Principal payments on Qualitest Pharmaceuticals debt | ||||
| Principal payments on other indebtedness | ||||
| Deferred financing fees | ||||
| Payment for contingent consideration | ||||
| Tax benefits of stock awards | ||||
| Payments of tax withholding for restricted shares | ||||
| Exercise of Endo Health Solutions Inc. stock options | ||||
| Purchase of common stock | ||||
| Issuance of common stock from treasury | ||||
| Cash distributions to noncontrolling interests | ||||
| Cash buy-out of noncontrolling interests, net of cash contributions | ||||
| Net cash provided by (used in) financing activities | ||||
| Effect of foreign exchange rate | ||||
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | ||||
| LESS: NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS OF DISCONTINUED OPERATIONS | ||||
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS OF CONTINUING OPERATIONS | ||||
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | ||||
| CASH AND CASH EQUIVALENTS, END OF PERIOD | ||||
| SUPPLEMENTAL INFORMATION: | ||||
| Cash paid for interest | ||||
| Cash paid for income taxes | ||||
| SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||
| Purchases of property, plant and equipment financed by capital leases | ||||
| Purchases of property, plant and equipment financed by direct financing arrangement | ||||
| Accrual for purchases of property, plant and equipment | ||||
Loading...
